112 related articles for article (PubMed ID: 38135634)
1. Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma.
Goldman-Mazur S; Visram A; Rajkumar SV; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Kumar SK
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e104-e111.e1. PubMed ID: 38135634
[TBL] [Abstract][Full Text] [Related]
2. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
Pasvolsky O; Gaballa MR; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Ramdial J; Nieto Y; Tang G; Lin P; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2023 Apr; 29(4):260.e1-260.e6. PubMed ID: 36646323
[TBL] [Abstract][Full Text] [Related]
3. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Guman T; Sykora J
Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
[TBL] [Abstract][Full Text] [Related]
4. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Pasvolsky O; Ghanem S; Milton DR; Masood A; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2023 Dec; 29(12):757-762. PubMed ID: 37673125
[TBL] [Abstract][Full Text] [Related]
6. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
8. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
9. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
Beksac M; Seval GC; Kanellias N; Coriu D; Rosiñol L; Ozet G; Goranova-Marinova V; Unal A; Bila J; Ozsan H; Ivanaj A; Balić LI; Kastritis E; Bladé J; Dimopoulos MA
Haematologica; 2020 Jan; 105(1):201-208. PubMed ID: 31278209
[TBL] [Abstract][Full Text] [Related]
10. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
[TBL] [Abstract][Full Text] [Related]
12. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
Sasaki K; Lu G; Saliba RM; Bashir Q; Hosing C; Popat U; Shah N; Parmar S; Dinh Y; Ahmed S; Shpall EJ; Kebriaei P; Shah JJ; Orlowski RZ; Champlin R; Qazilbash MH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1227-32. PubMed ID: 23733001
[TBL] [Abstract][Full Text] [Related]
13. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)].
Wang Y; Liu YF; Tao Y; Jin SW; Mi JQ
Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2868-2873. PubMed ID: 36153872
[No Abstract] [Full Text] [Related]
15. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.
Pasvolsky O; Milton DR; Rauf M; Tanner MR; Bashir Q; Srour S; Tang G; Saini N; Ramdial J; Masood A; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2022 Nov; 28(11):752.e1-752.e6. PubMed ID: 35940528
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
Afrough A; Alsfeld LC; Milton DR; Delgado R; Popat UR; Nieto Y; Kebriaei P; Oran B; Saini N; Srour S; Hosing C; Cheema FH; Ahmed S; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Weber DM; Orlowski RZ; Pinnix CC; Dabaja BS; Thomas SK; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
Transplant Cell Ther; 2023 Apr; 29(4):264.e1-264.e9. PubMed ID: 35605883
[TBL] [Abstract][Full Text] [Related]
18. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
19. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
[No Abstract] [Full Text] [Related]
20. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
Tao Y; Jin SW; Wang Y; Tang SJ; Liu YF; Xu J; Pan MM; Zhang WP; Mi JQ
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):48-54. PubMed ID: 36987723
[No Abstract] [Full Text] [Related]
[Next] [New Search]